Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H1, 2019

GlobalData's clinical trial report, “Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H1, 2019" provides an overview of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) clinical trials scenario. This report provides top line data relating to the clinical trials on Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

GW Pharmaceuticals Plc

Biocodex

Zogenix Inc

Takeda Pharmaceutical Co Ltd

EpyGenix Therapeutics Inc

Sage Therapeutics Inc

Ovid Therapeutics Inc

Stoke Therapeutics Inc

Spera Pharma Inc ...

GW Pharmaceuticals Plc

Biocodex

Zogenix Inc

Takeda Pharmaceutical Co Ltd

EpyGenix Therapeutics Inc

Sage Therapeutics Inc

Ovid Therapeutics Inc

Stoke Therapeutics Inc

Spera Pharma Inc

Insys Therapeutics Inc

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region ...

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Countries Contributing to Clinical Trials in Middle East and Africa 14

Clinical Trials by G7 Countries: Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials 15

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials 20

Clinical Trials by Phase in E7 Countries 22

Clinical Trials in E7 Countries by Trial Status 23

Clinical Trials by Phase 24

In Progress Trials by Phase 25

Clinical Trials by Trial Status 26

Clinical Trials by End Point Status 28

Subjects Recruited Over a Period of Time 29

Clinical Trials by Sponsor Type 30

Prominent Sponsors 31

Top Companies Participating in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials 33

Prominent Drugs 35

Clinical Trial Profile Snapshots 37

Appendix 94

Abbreviations 94

Definitions 94

Research Methodology 95

Secondary Research 95

About GlobalData 96

Contact Us 96

Source 97

List of Tables

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Region, 2019* 7

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical ...

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Region, 2019* 7

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 8

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2019* 11

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 12

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, North America, Top Countries, 2019* 13

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 14

Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 15

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18

Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 20

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 22

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 23

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Phase, 2019* 24

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 25

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 26

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 28

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 29

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 30

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 31

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 33

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 35

List of Figures

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Region (%), 2019* 7

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, ...

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Region (%), 2019* 7

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 8

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2019* 11

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 12

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 13

Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 15

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18

Proportion of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 20

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 22

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 23

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 24

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 25

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 26

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 28

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 29

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 30

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 31

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 33

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 35

GlobalData Methodology 95

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports